期刊文献+

甲苯磺酸索拉非尼有关物质的合成 被引量:1

Synthesis of Related Substance of Sorafenib Tosylate
下载PDF
导出
摘要 为了控制抗癌药甲苯磺酸索拉非尼产品质量,制备了可能的5种有关物质,4-(4-氨基甲酸乙酯苯氧基)-N-甲基-2-吡啶甲酰胺(A),4-氯-3-(三氟甲基)苯胺(B),4-氯-3-三氟甲基苯基氨基甲酸乙酯(C),1,3-二(4-氯-3-(三氟甲基)苯基)脲(D),4-(4-{3-[3-(三氟甲基)苯基]脲基}苯氧基)-N2-甲基吡啶-2-羧酰胺(E),并经1H-NMR,13CNMR,ESI-MS等确证结构。 To perform the quality control of anticarcinogen drug sorafenib tosylate,five related substanceswere prepared,and their structures were confirmed by1H- NMR,13C- NMR and ESI- MS. These substances were ethyl( 4-(( 2-( methyl- carbamoyl) pyridin- 4- yl) oxy) phenyl) carbamate( A),4- chloro- 3-( trifluoromethyl) aniline( B),ethyl( 4- chloro- 3-( trifluoromethyl) phenyl) carbamate( C),1,3- bis( 4- chloro- 3-( trifluoromethyl) phenyl) urea( D),4-( 4-( 3-( 3-( trifluoromethyl) phenyl) ureido) phenoxy)- N- methyl picolinamide( E).
出处 《山东化工》 CAS 2016年第2期37-39,42,共4页 Shandong Chemical Industry
关键词 抗癌药 甲苯磺酸索拉非尼 有关物质 合成 anticarcinogen drug sorafenib tosylate related substance synthesis
  • 相关文献

参考文献5

二级参考文献42

  • 1钱帅,张建军,高缘,周建平.纳米混悬剂研究进展[J].药学进展,2007,31(1):9-14. 被引量:16
  • 2[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004 Oct 1; 64 (19):7099-109.
  • 3[2]Strumberg D,Richly H,Hilger RA,et al.Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006in patients with advanced refractory solid tumors.J Clin Oncol,2005,23 (5):965
  • 4[3]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC).J Clin Oncol,2005,23 (16S):Abstract 4544
  • 5[4]Flaherty KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin (C) and paclitaxel (P)demonstrates preliminary antitumor activity in the expansion chort of patients with metastatic melanoma.Proc Am Society Clin Oncol,2004,23:Abstract 7507
  • 6[5]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43 -9006) in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17 (5):866
  • 7[6]Siu LL,Awada A,Takimoto CH,et al.Phase Ⅰ trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.Clin Cancer Res,2006,12 (1):144
  • 8[7]Kupsch P,Henning BF,Passarge K,et al.Results of a phaseⅠ trial of sorafenib (BAY 43 -9006) in combination with oxaliplatin in patients with refractory solid tumors,including colorectal cancer.Clin Colorectal Cancer,2005,5 (3):188
  • 9[8]Clark JW,Eder JP,Ryan D,et al.Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor,BAY 43 -9006,in patients with advanced,refractory solid tumors.Clin Cancer Res,2005,1; 11 (15):5472
  • 10[9]Strumberg D,Awada A,Hirte H,et al.Pooled safety analysis of BAY 43 -9006 (sorafenib) monotherapy in patients with advanced solid tumors:Is rash associated with treatment outcome? Eur J Cancer,2006,42 (4):548

共引文献63

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部